PPI Refractory - GERD Mechanisms in Systemic Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

147 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about the mechanisms of gastroesophageal reflux disease (GERD) in patients with systemic sclerosis (SSc) who continue to experience reflux symptoms despite treatment with proton pump inhibitors (PPIs). The main question it aims to answer is:

What are the underlying gastrointestinal mechanisms contributing to PPI-refractory reflux symptoms in patients with SSc?

Participants with a confirmed diagnosis of SSc and persistent reflux symptoms despite PPI therapy will undergo standard-of-care diagnostic tests, including high-resolution esophageal manometry and pH-impedance monitoring. Clinical data and test results will be collected and analyzed to identify patterns of motility dysfunction and reflux characteristics associated with refractory symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.

NCT01601379

Gastroesophageal Reflux Disease Gastro-oesophageal Reflux Gastro-Esophageal Reflux +2 more

COMPLETED

Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients

NCT01212614

Gastroesophageal Reflux Disease Healthy Volunteers

COMPLETED NA

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939

Gastroesophageal Reflux Disease

COMPLETED PHASE2

A Prospective, Observational Study of the PPI Non-responder

NCT03282084

Gastro Esophageal Reflux Disease PPI Non-Responders

WITHDRAWN

Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease

NCT00200642

Gastroesophageal Reflux Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

Gastroesophageal reflux disease (GERD) is one of the most frequent gastrointestinal manifestations in patients with systemic sclerosis (SSc). However, a significant proportion of these patients experience symptoms that are refractory to treatment with proton pump inhibitors (PPIs), suggesting the involvement of underlying pathophysiological mechanisms that are not yet fully defined. Motor dysfunction in other segments of the gastrointestinal tract may contribute to this refractoriness, but studies addressing this in the SSc population have been limited. Currently, there are no personalized diagnostic algorithms that integrate symptoms, objective motility findings, and clinical characteristics in patients with SSc and GERD. Our goal is to identify the mechanisms associated with the severity of PPI-refractory GERD in SSc and to develop a practical and cost-effective diagnostic model based on objective data to enable personalized medicine.

Hypothesis:

PPI-refractory GERD in patients with systemic sclerosis can be assessed more sensitively and accurately through objective evaluation of motility across different gastrointestinal organs.

Objective:

To assess the pathophysiological mechanisms associated with the severity of refractory GERD in patients with SSc using objective motility tests and clinical markers, and to develop a diagnostic algorithm to guide personalized treatment based on the organ affected.

Methods:

This is a prospective clinical cohort study. Patients with SSc and symptoms of GERD refractory to PPIs will be included. Clinical, immunological, and demographic variables will be collected. Esophageal symptoms and quality-of-life impact will be assessed using validated questionnaires. Advanced gastrointestinal motility tests (gastric emptying scintigraphy and high-resolution intestinal manometry) will be performed to evaluate mechanisms associated with reflux severity (presence of erosive esophagitis and esophageal acid exposure).

Relevance:

This study addresses a common clinical challenge in patients with SSc: the persistence of GERD symptoms despite acid-suppressive treatment with PPIs. This project proposes to elucidate the pathophysiological mechanisms associated with GERD severity using motility tests available in clinical practice, and to develop a personalized approach based on objective motility assessment. This will allow the identification of the underlying mechanisms of treatment-refractory GERD and, in the future, the evaluation of targeted therapies addressing the associated dysmotility. The development of a diagnostic algorithm will support clinical decision-making, promote rational use of invasive tests, and optimize patient management, with a potential impact on improving quality of life and healthcare efficiency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Sclerosis (SSc) GERD (Gastroesophageal Reflux Disease)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with SSc and PPI-refractory GERD symptoms

Study Subjects:

Patients will be recruited from the outpatient clinics of the Autoimmune Diseases Unit or the Gastroenterology Department at the Vall d'Hebron University Hospital (HUVH), Barcelona.

Inclusion Criteria:

Diagnosis of systemic sclerosis according to the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria and/or LeRoy criteria.

Age ≥ 18 years.

Presence of gastroesophageal reflux symptoms, defined as heartburn and/or regurgitation occurring at least three times per week over the past three months, despite ongoing treatment with PPIs.

educational healthcare intervention

Intervention Type OTHER

This intervention will be applyed at the beginning of the study

Objective assessment of GI motility

Intervention Type DIAGNOSTIC_TEST

Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.

Evaluation of GERD severity

Intervention Type DIAGNOSTIC_TEST

Objective evaluation of GERD severity on PPI therapy will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

educational healthcare intervention

This intervention will be applyed at the beginning of the study

Intervention Type OTHER

Objective assessment of GI motility

Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.

Intervention Type DIAGNOSTIC_TEST

Evaluation of GERD severity

Objective evaluation of GERD severity on PPI therapy will be performed.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

avoiding late dinners not lying down for at least 2 hours after meals avoiding tobacco and alcohol avoiding large or high-fat meals Gastric emptying test Small bowel manometry High-resolution esophageal manometry Abdominal CT scan upper GI endoscopy (on PPI) pH-impedance monitoring (on PPI)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Systemic sclerosis by ACR/EULAR 2023 criteria AND/OR Leroy Medsger classification criteria
* Reflux symptoms (Heartburn AND/OR Regurgitation), at least 3 times a week over the last 3 months despite PPI therapy

Exclusion Criteria

* Previous surgery altering the anatomy or motility of the upper digestive tract, including fundoplication, esophageal myotomy, gastrectomy, or bariatric surgery.

Severe pulmonary or cardiac disease requiring intravenous vasodilators, continuous oxygen therapy, or ventricular assist devices, preventing the performance of gastrointestinal motility tests.

Pregnancy at the time of evaluation or planned pregnancy during the duration of the study.

Neuromuscular disorders other than systemic sclerosis that may affect gastrointestinal motility.

Prior diagnosis of functional gastrointestinal disorders, such as irritable bowel syndrome or functional dyspepsia, that may interfere with the interpretation of results.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No